Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pyrathiazine theoclate + pyridoxine hydrochloride
- Development stage
- Unknown
- Lead developer
- PT Tunggal Idaman Abadi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Voldiamer B6 is an oral fixed-dose combination therapy developed by Tunggal Idaman Abdi for the prevention and treatment of nausea and vomiting. It is primarily indicated for morning sickness (nausea and vomiting of pregnancy), post-surgical vomiting, and motion sickness. The formulation consists of pyrathiazine theoclate, a first-generation phenothiazine antihistamine, and pyridoxine hydrochloride (vitamin B6). Pyrathiazine theoclate acts as an antagonist at central histamine H1 receptors, inhibiting the gag reflex in the chemoreceptor trigger zone (CTZ) and stabilizing vestibular pathways. Pyridoxine hydrochloride serves as a precursor to pyridoxal 5'-phosphate (PLP), an essential cofactor that modulates neurotransmitter synthesis (such as GABA) to further alleviate emetic symptoms.
- Brand names
- Anvomer B6Emegrav B6Mediamer B6Pontyamer B6PregvomitProvomerVoldiamer B6Vomil B6
- Other names
- pyrathiazine + pyridoxinepyrathiazine theoclate + pyridoxine HClpyrathiazine theoclate and pyridoxine HClpyrathiazine theoclate and pyridoxine hydrochloridepyrathiazine theoclate/pyridoxine hydrochloridepyrathiazine/pyridoxine
02
Targets
HRH1 (Histamine H1 Receptor)mAChR (Muscarinic acetylcholine receptors)
Beyond the preview
Go deeper on pyrathiazine theoclate + pyridoxine hydrochloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pyrathiazine theoclate + pyridoxine hydrochloride.